As we wait for the Canadian courts to repeat the process that made cannabis legal after decades in purgatory, some companies aren’t waiting around for their chance to claim a piece of the upcoming shroomaceuticals market.
CBD product developer/retailer Yield Growth Corp (BOSS.C) has announced it has agreed to acquire 18% of Translational Life Sciences, a company that “aims to develop proprietary formulations using restricted substances to focus on unmet medical needs in opioid dependence, psychotic illness, pain management and traumatic brain injury, including concussion.”
50 years I’ve been bumbling around this planet, and the best damn weekend I’ve had on it to date occurred recently, under the influence of mushrooms.
Roadman Investments (LITT.V) is forming a California-based joint-venture with lifestyle centre Psychedelic Insights to open the first psilocybin therapy centre in the United States when the states get around to legalizing it.
The shroom-boom continues to develop as the City of Santa Cruz is the latest to decriminalize magic mushrooms.
Graph Blockchain’s (GBLC.C) latest shroom-venture shows they’re not willing to raise the white flag yetJanuary 24, 2020
Graph Blockchain’s (GBLC.C) story is either going to be one of ultimate failure—an object lesson of what not to do for new companies—or an absolutely great comeback story, but what’s obvious is that they’re not willing to fly the white flag anytime soon.
Yield Growth (BOSS.C) subsidiary Flourish Mushrooms forms JV to do research and development in paradiseJanuary 7, 2020
Flourish Mushroom Labs, a subsidiary of Yield Growth (BOSS.C), entered into a binding letter of intent with Acres Agricultural Canada to form a JV in Saint Vincent and the Grenadines for the cultivation of psilocybin mushrooms, and for research and development into compounds and therapeutic uses for psychedelic mushrooms.